Subscribe to RSS
Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic PatientsFunding This study was supported by grants from the National Natural Science Foundation of China (81970704, 81970689, 81900787, 81800752, and 81800719), National Key Research and Development Program of China (2016YFC1304804 and 2017YFC1309605), Jiangsu Provincial Key Medical Discipline (ZDXKB2016012), Key Project of Nanjing Clinical Medical Science, Key Research and Development Program of Jiangsu Province of China (BE2015604 and BE2016606), Medical and Health Research Projects of Nanjing in Jiangsu Province of China (YKK18067), Project of Standardised Diagnosis and Treatment of Key Diseases in Jiangsu Province of China (2015604), and Natural Science Foundation of Jiangsu Province of China (BK20201115). Drum Tower Hospital (affiliated with Nanjing University Medical School, China) provided sponsorship for article processing charges.
Purpose We compared the efficacy and safety of beinaglutide, a glucagon-like peptide-1 (GLP-1) analogue with metformin in lowering the bodyweight of patients who were overweight/obese and non-diabetic.
Patients and Methods Seventy-eight non-diabetic patients were randomly selected and beinaglutide or metformin was administered for 12 weeks. The primary endpoints were changes in body weight and the proportions of patients who lost≥5 and≥10% of their baseline body weights.
Results A total of 64 patients completed the study; patients in the beinaglutide group exhibited more bodyweight loss than those in the metformin group [(9.5±0.8%; 9.1±0.9 kg) and (5.1±0.9%; 4.5±0.8 kg), respectively, corresponding to a difference of approximately 4.5 kg (95% confidence interval, 2.2–6.9 kg; P<0.01)]. In the beinaglutide group, 90.6 and 40.6% of the patients lost≥5 and≥10% of their body weight, respectively, whereas, in the metformin group, these rates were 46.9 and 12.5%, respectively (P<0.01 and P<0.05). Weight loss following beinaglutide treatment mainly resulted from the loss of fat mass. Compared to metformin, beinaglutide induced a greater decrease in the body mass index, weight circumference, percent body fat, and body fat mass (total, trunk, limb, android, and gynoid). Additionally, beinaglutide decreased serum insulin levels and ameliorated insulin resistance.
Conclusions Beinaglutide is more efficient than metformin at reducing weight and fat mass in patients who are overweight/obese and non-diabetic. Beinaglutide may be a useful therapeutic option for overweight/obesity control in the Chinese population.
Key wordsGlucagon-like peptide-1 receptor agonist - Biguanides - Weight loss ratio - Body composition
Received: 02 March 2021
Received: 27 July 2021
Accepted: 10 August 2021
Article published online:
02 December 2021
© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 American Diabetes A Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2020. Diabetes Care 2020; 43: S89-S97
- 2 Mertens IL, Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obesity (Silver Spring, Md.) 2000; 8: 270-278
- 3 Warkentin LM, Das D, Majumdar SR. et al. The effect of weight loss on health-related quality of life: systematic review and meta-analysis of randomized trials. Obesity Rev 2014; 15: 169-182
- 4 Ma C, Avenell A, Bolland M. et al. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. Br Med J 2017; 359: j4849
- 5 Bray GA, Fruhbeck G, Ryan DH. et al. Management of obesity. Lancet 2016; 387: 1947-1956
- 6 Dombrowski SU, Knittle K, Avenell A. et al. Long term maintenance of weight loss with non-surgical interventions in obese adults: Systematic review and meta-analyses of randomised controlled trials. Br Med J 2014; 348: g2646
- 7 Pi-Sunyer X, Astrup A, Fujioka K. et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373: 11-22
- 8 van Bloemendaal L, Ten Kulve JS, la Fleur SE. et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 2014; 221: T1-T16
- 9 Klonoff DC, Buse JB, Nielsen LL. et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275-286
- 10 Vilsboll T, Christensen M, Junker AE. et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Br Med J 2012; 344: d7771-d7771
- 11 Flint A, Raben A, Ersboll AK. et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001; 25: 781-792
- 12 Society CD. Chinese guideline for the prevention and treatment of type 2 diabetes mellitus (2020 edition). Chin J Endo Metab 2021; 37: 311-398
- 13 Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728-742
- 14 Application Manual for Benalutide Injection (Yishengtai). Approval Number: S20160007, Shanghai Renhui Bio-Pharmaceutical Co., Ltd.
- 15 Zhang YL, Zhou C, Li XF. et al. Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: A 3–month, multicentre, observational, retrospective, open-label study. Obes Sci Pract 2019; 5: 366-375
- 16 American Diabetes A Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care 2018; 41: S73-s85
- 17 Desilets AR, Dhakal-Karki S, Dunican KC. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother 2008; 42: 817-826
- 18 Zhou J, Massey S, Story D. et al. Metformin: an old drug with new applications. Int J Mol Sci 2018; 19: 2863
- 19 Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes 2013; 121: 27-31
- 20 Hui F, Zhang Y, Ren T. et al. Role of metformin in overweight and obese people without diabetes: A systematic review and network meta-analysis. Eur J Clin Pharmacol 2019; 75: 437-450
- 21 Guideline for primary care of obesity:practice version. 2019; Chin J Gen Pract 2020: 102-103
- 22 Domecq JP, Prutsky G, Leppin A. et al. Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015; 100: 363-370
- 23 Jensterle M, Kravos NA, Goričar K. et al. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord 2017; 17: 5
- 24 Liu X, Zhang Y, Zheng S. et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol 2017; 87: 767-774
- 25 O'Neil PM, Birkenfeld AL, McGowan B. et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018; 392: 637-649
- 26 Apovian CM, Aronne LJ, Bessesen DH. et al. Pharmacological management of obesity: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100: 342-362
- 27 Feng WH, Bi Y, Li P. et al. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial. J Diabetes Investig 2019; 10: 399-407
- 28 Larsen JR, Vedtofte L, Jakobsen MSL. et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: A randomized clinical trial. JAMA Psychiatry 2017; 74: 719-728
- 29 Jendle J, Nauck MA, Matthews DR. et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009; 11: 1163-1172
- 30 Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018; 27: 740-756
- 31 Feng W, Gao C, Bi Y. et al. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. J Diabetes 2017; 9: 800-809
- 32 Armstrong MJ, Gaunt P, Aithal GP. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387: 679-690
- 33 Doyle ME, Egan JM. Mechanisms of action of GLP-1 in the pancreas. Pharmacol Ther 2007; 113: 546-593
- 34 Tsushima Y, Nishizawa H, Tochino Y. et al. Uric acid secretion from adipose tissue and its increase in obesity. J Biol Chem 2013; 288: 27138-27149
- 35 Piaggi P, Thearle MS, Bogardus C. et al. Lower energy expenditure predicts long-term increases in weight and fat mass. J Clin Endocrinol Metab 2013; 98: E703-E707
- 36 Palmer BF, Clegg DJ. Strategies to counter weight loss-induced reductions in metabolic rate. Curr Sport Med Rep 2019; 18: 258-265